InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Orelabrutinib in Combination with Tafasitamab + Lenalidomide in China streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022 10.12.2022 / 23:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release PLANEGG/MUNICH, Germa.
Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) for the third quarter of 2022 Presentation of preliminary results from phase 1/2 study of tulmimetostat (CPI-0209) supporting its
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results 16.11.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 16, 2022 MorphoSys AG.
MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.